Company / SG&A Expense
SELLAS Life Sciences Group, Inc. SG&A Expense History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$12.4M
FY2024
5-year range
$9.6M / $13.9M
FY2020-FY2024
Trend
-10.4%
vs FY2023
Sector context
#207 of 213
Health Care
What the data says
Among 213 Health Care companies, SELLAS Life Sciences Group, Inc. is in the top 3% for sg&a expense. Increased from $11M to $12M over the past 2 years.
Based on SEC 10-K filings.
$12M in FY2024 with a 5-year CAGR of +4.6%.
Increased from $11M to $12M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.0%
- 5-Year CAGR
- +4.6%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $12.4M Sector average $722.3M
▼
-98.3% below sector average
Key checks
Key Insights
- 5-year CAGR of +4.6%, indicating consistent growth.
- In FY2024, sg&a expense decreased 10.4% year-over-year.
- Ranks #207 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.39 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $12.4M | -10.4% |
| FY2023 | $13.9M | +22.5% |
| FY2022 | $11.3M | +17.9% |
| FY2021 | $9.6M | +0.0% |
| FY2020 | $9.6M | -3.3% |
| FY2019 | $9.9M | -22.3% |
| FY2018 | $12.8M | -15.4% |
| FY2017 | $15.1M | +228.5% |
| FY2016 | $4.6M | - |
| FY2015 | - | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026